Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6534070 | LEO PHARMA AS | Composition with azelaic acid |
Nov, 2018
(5 years ago) | |
US6730288 | LEO PHARMA AS | Mousse composition |
Sep, 2019
(4 years ago) | |
US10322085 | LEO PHARMA AS | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
Oct, 2023
(6 months ago) | |
US8900554 | LEO PHARMA AS | Foamable composition and uses thereof |
Oct, 2023
(6 months ago) | |
US8722021 | LEO PHARMA AS | Foamable carriers |
Oct, 2023
(6 months ago) | |
US8435498 | LEO PHARMA AS | Penetrating pharmaceutical foam |
Mar, 2024
(2 months ago) | |
US7700076 | LEO PHARMA AS | Penetrating pharmaceutical foam |
Sep, 2027
(3 years from now) | |
US10117812 | LEO PHARMA AS | Foamable composition combining a polar solvent and a hydrophobic carrier |
Oct, 2027
(3 years from now) | |
US9265725 | LEO PHARMA AS | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
Dec, 2027
(3 years from now) | |
US9211259 | LEO PHARMA AS | Antibiotic kit and composition and uses thereof |
Feb, 2029
(4 years from now) |
Finacea is owned by Leo Pharma As.
Finacea contains Azelaic Acid.
Finacea has a total of 10 drug patents out of which 6 drug patents have expired.
Expired drug patents of Finacea are:
Finacea was authorised for market use on 24 December, 2002.
Finacea is available in aerosol, foam;topical dosage forms.
Finacea can be used as topical treatment of inflammatory papules and pustules of mild to moderate rosacea.
The generics of Finacea are possible to be released after 28 February, 2029.
Drugs and Companies using AZELAIC ACID ingredient
Market Authorisation Date: 24 December, 2002
Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea
Dosage: AEROSOL, FOAM;TOPICAL